This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Lyman G, Lalla A, Barron R, Dubois RW.Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion 25: 401-411, No. 2, Feb 2009
Rights and permissions
About this article
Cite this article
Pegfilgrastim worth it for preventing febrile neutropenia. Pharmacoecon. Outcomes News 574, 7 (2009). https://doi.org/10.2165/00151234-200905740-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905740-00015